Abstract

BackgroundFor individuals with cervical cancer, large tumor volume, lymph node metastasis, distant metastasis, and parauterine infiltration are usually associated with a poor prognosis. Individuals with stage 1B1 and 1B2 cervical cancer usually do not have these unfavorable prognostic factors. Once the disease progresses, the prognosis becomes extremely poor. Therefore, investigating the prognostic markers of these cervical cancer patients is necessary for treatment.MethodsThis retrospective study included 95 cervical cancer patients treated with surgery. The patients were divided into progressor and non-progressor groups according to postoperative follow-up results. T-test (or Mann−Whitney U test), chi-squared test (or Fisher’s exact test) and receiver operating characteristic (ROC) curves were used to evaluate imaging, hematology, and clinicopathological index differences between the two groups. Cox analysis was performed to select the independent markers of progression-free survival (PFS) when developing the nomogram. Validation of the nomogram was performed with 1000 bootstrapped samples. The performance of the nomogram was validated with ROC curves, generated calibration curves, and Kaplan-Meier and decision curve analysis (DCA).ResultsCervical stromal invasion depth, lymphovascular space invasion (LVSI), human papilloma virus (HPV-16), Glut1, D-dimer, SUVmax and SUVpeak showed significant differences between the two groups. Multivariate Cox proportional hazard model showed SUVpeak (p = 0.012), and HPV-16 (p = 0.007) were independent risk factors and were used to develop the nomogram for predicting PFS. The ROC curves, Kaplan-Meier method, calibration curves and DCA indicated satisfactory accuracy, agreement, and clinical usefulness, respectively.ConclusionsSUVpeak level (≥7.63 g/cm3) and HPV-16 negative status before surgery were associated with worse PFS for patients with cervical cancer. Based on this result, we constructed the nomogram and showed satisfactory performance. Clinically, individualized clinical decision-making can be performed on patients based on this result.

Highlights

  • Cervical cancer has the second highest incidence of female malignant tumors [1]

  • The International Federation of Gynecology and Obstetrics (FIGO) cancer staging system is used in the formulation of treatment and prognosis plans for patients with cervical cancer

  • Radical hysterectomy with lymphadenectomy will be effective for those cervical cancer patients with the following characteristics: invasive carcinoma confined to the uterine cervix, no more than 5 mm invasion, tumor size < 4 cm in its greatest dimension and no lymph node metastasis

Read more

Summary

Introduction

Cervical cancer has the second highest incidence of female malignant tumors [1]. The International Federation of Gynecology and Obstetrics (FIGO) cancer staging system is used in the formulation of treatment and prognosis plans for patients with cervical cancer. Radical hysterectomy with lymphadenectomy will be effective for those cervical cancer patients (stage 1B1, 1B2) with the following characteristics: invasive carcinoma confined to the uterine cervix, no more than 5 mm invasion, tumor size < 4 cm in its greatest dimension and no lymph node metastasis. These patients often do not need postoperative adjuvant radiotherapy, since, radiotherapy has serious side effects [5]. For individuals with cervical cancer, large tumor volume, lymph node metastasis, distant metastasis, and parauterine infiltration are usually associated with a poor prognosis. Investigating the prognostic markers of these cervical cancer patients is necessary for treatment

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call